Your session is about to expire
← Back to Search
AP-PA02 for Cystic Fibrosis (SWARM-Pa Trial)
SWARM-Pa Trial Summary
This trialtests the safety and effects of inhaling a drug to fight lung infections in people with cystic fibrosis.
- Cystic Fibrosis
- Pneumonia
- Pseudomonal Lung Infection
- Pseudomonas Infections
- Pseudomonas Aeruginosa
SWARM-Pa Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSWARM-Pa Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 1 & 2 trial • 29 Patients • NCT04596319SWARM-Pa Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any opportunities for enrollment in this experiment currently?
"As recorded on clinicaltrials.gov, this experiment is actively recruiting participants to participate in the study which was posted and last updated respectively on December 22nd 2020 and November 24th 2021."
What is the scope of this experiment in terms of participating locations?
"The trial is available at 17 locations throughout the country, including Boston, Chicago and Iowa City. It is suggested that patients pick a site close to them in order to limit transportation costs for participants."
How many participants is the clinical trial limited to?
"Armata Pharmaceuticals, Inc. is the primary sponsor of this clinical trial and will be running it from Boston Children's Hospital in MA as well as Northwestern University in IL. For the investigation to commence 48 qualifying individuals are necessary."
Share this study with friends
Copy Link
Messenger